Tumor immune microenvironment (TIME) consists of intra-tumor immunological components
and plays a significant role in tumor initiation, progression, metastasis, and response to …

Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …

A major rate-limiting step in developing more effective immunotherapies for GBM is our
inadequate understanding of the cellular complexity and the molecular heterogeneity of …

Background Malignant glioma is the most common and lethal primary brain tumour, with
dismal survival rates and no effective treatment. We examined the safety and activity of NSC …

Primary brain tumors, such as glioblastoma (GBM), are remarkably resistant to
immunotherapy, even though pre-clinical models suggest effectiveness. To understand this …

There has been no significant improvements for immune checkpoint inhibitors since its first
use. Tumour-associated macrophages (TAMs) are critical mediators in the PD-1/PD-L1 axis …

Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous
system in adults. Ever more recent papers are focusing on understanding the role of the …

Tumor microenvironment (TME) is the cornerstone of the occurrence, development, invasion
and diffusion of the malignant central nerve system (CNS) tumor, glioma. As the largest …

Background Glioblastoma (GBM) is refractory to immune checkpoint inhibitor (ICI) therapy.
We sought to determine to what extent this immune evasion is due to intrinsic properties of …

Background: tumor-infiltrating lymphocytes are prognostic in many human cancers.
However, the prognostic value of lymphocytes infiltrating glioblastoma (GBM), and roles in …